The number of people without homes counted in Greater Victoria this spring was up about five per cent from two years ago, say organizers of the annual Point-in-Time Count. The final tally from the ...
Readers propose ideas for “How Catholics Can Solve the Vocations Crisis” (Letters, Oct. 4), and some are worth pursuing. But the underlying report on the church’s “manpower problem” paints too gloomy ...
As an individual investor, I know firsthand how the demands of daily life can lead to unread mail from companies and missed chances to vote on shareholder proposals and director elections. When you ...
After a manic week that began with Japanese stocks falling to their worst loss since 1987's Black Monday, only for U.S. stocks to soar later to their best day since 2022, slight gains on Friday ...
US oil and gas drilling rig activity increased this week with the addition of 7 rigs, bringing the total working rigs to 549. This week’s count, however, is down 38 rigs from the comparable period a ...
Tyson Fury was seen for the first time after his daughter's engagement as he joined fellow sports star and Coronation Street actors for a 'scary' time. The professional boxer enjoyed an afternoon with ...
Michigan officials say additional bodies were discovered in the church, raising the total to four fatal victims, plus the suspect, Thomas Jacob Sanford, as the fifth deceased, according to Grand Blanc ...
They held auditions in August at the Farmville Community Arts Council and I was so sorry to miss it. I’ve always believed that everyone (introverts and shy folks included) should be part of a live ...
CHARLESTON, S.C. (WCBD) – The College of Charleston will host its third community meeting Monday on the Coming Street Commons project. Leaders say the building also sits on top of a potter’s field, ...
In its latest bid to boost semiconductor production in the U.S., the Trump administration is reportedly considering a ratio-based approach that would penalize domestic manufacturers with tariffs if ...
Marengo Therapeutics, Inc., a clinical-stage biotech company, develops novel TCR-targeting antibodies that selectively modulate common and disease-specific T cell subsets of the germline TCR ...
- Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer selected for presentation in an ESMO Presidential Symposium - TOKYO, ...